ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

The company noted that its Phase 2 community study, known as POSITS, has started with the first participants being dosed in ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Mutuum Finance (MUTM) has reported progress on its development roadmap as the project prepares for the release of its V1 ...